19 May 2022

Interim Report 1 January – 31 March 2022

Scandion Oncology (Scandion) today announces its interim report for Q1 2022. The following is taken from the report.

Bo Rode Hansen, President and CEO, comments

“It is with pleasure that we report on our activities for the first quarter of 2022. It has been a good start to the year with solid operations, continued execution of our strategy and implemen­tation of our plans. I am looking at a company “punching above its weight” in several ways.”

Key Figures & Highlights

TDKK Q1 2022 Q1 2021 FY 2021
Operating loss -16,312 -9,904 -55,367
Net finance income/cost -251 -1,350 -1,846
Loss before tax -16,563 -11,254 -57,213
Net loss -12,919 -8,855 -51,705
Total assets 101,259 154,080 116,219
Cash Position 87,965 145,216 105,710
Total equity 91,672 147,101 104,541
Equity ratio 91% 95% 90%
Earnings per share (EPS) -0.40 -0.28 -1.61
Shares outstanding, ending 32,135,544 21,293,396 32,135,544

Highlights during Q1 2022

  • On January 12, Scandion Oncology announced that Mads Kronborg, bringing more than a decade of corporate communication and investor relations expe­rience in the global life-science industry, will now help plan and drive its external communication as Head of External Communication.
  • On January 18, Scandion Oncology announced that data with the Company’s lead compound SCO-101 as combination therapy in patients with metastatic colorectal cancer was accepted for poster presentation at the ASCO Gastrointestinal Cancers Symposium.
  • On February 2, Scandion Oncology announced approval from the German and Spanish regulatory authorities to expand part 2 of the CORIST Phase II study to Germany and Spain.

Highlights after the end of the period

  • On May 11, Scandion Oncology enhances manage­ment and clinical development function with appoint­ment of global executive as Chief Medical Officer. Dr. Alfredo Zurlo brings decades of experience from clinical development in oncology.

The interim report Q1 2022 is available on the Company’s website:

Audiocast today, May 19 at 10:00 am CET

Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.

At the end of the presentation there will be a Q&A session.

Access to the event can be obtained as follows:

REPLAY access:

Webcast replay will be available at in the Investors section and at

For further information please contact:

Mads Kronborg, Head of External Communication

Phone: +45 6051 4955


The information was provided by the contact person above for publication on May 19, 2022, at 08.30 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers as oral add-on drugs to existing market leading therapies. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). 

Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at or +46 (0) 40 200 250.